USPTO Examiner NOTTINGHAM KYLE GREGORY - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18754049NONIONIC POLYETHER SURFACTANTSJune 2024June 2025Allow1110NoNo
18636731AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORSApril 2024February 2025Allow1000NoNo
18598033METHOD FOR SEPARATING FLAVOKAWAIN AND KAVALACTONE, KAVALACTONE, AND MICROENCAPSULATED KAVALACTONEMarch 2024September 2024Allow610NoNo
18392193SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAMEDecember 2023March 2025Allow1510NoNo
18368099CRYSTALLINE HYDROCHLORIDE SALTS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINESeptember 2023August 2024Allow1121NoNo
18180181CDK Inhibitors And Their Use As PharmaceuticalsMarch 2023May 2025Abandon2611NoNo
18172656POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITORFebruary 2023April 2024Allow1411YesNo
18171822SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAMEFebruary 2023March 2025Allow2442YesNo
18106290METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASESFebruary 2023March 2024Allow1310YesNo
18164286METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDSFebruary 2023August 2024Abandon1920YesNo
18161402Scalp Numbing SystemJanuary 2023August 2024Abandon1921NoNo
18099291PHARMACEUTICAL COMPOSITION FOR TREATING LOCALLY ADVANCED MISMATCH REPAIR-PROFICIENT/MICROSATELLITE STABLE (PMMR/MSS) COLORECTAL CANCER (CRC) AND USE THEREOFJanuary 2023June 2024Allow1711NoNo
18154349TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONSJanuary 2023May 2024Abandon1610NoNo
17990321Drug delivery via contact lenses and similar ophthalmic devicesNovember 2022April 2024Abandon1710YesNo
18047497BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORSOctober 2022September 2024Allow2311NoNo
17936508PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOFSeptember 2022January 2024Abandon1601NoNo
17906367COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACIDSeptember 2022May 2025Allow3200NoNo
17941611INHIBITORS OF C. DIFFICILE SPORE GERMINATIONSeptember 2022June 2024Allow2221NoNo
17821314METHODS OF IRON CATALYZED C-H BOND AMINATIONAugust 2022May 2024Allow2111YesNo
17866227IL-17 LIGANDS AND USES THEREOFJuly 2022August 2024Allow2511YesNo
17724724COMPOUNDS AS LXR AGONISTSApril 2022June 2024Abandon2601NoNo
17622608PROMOTING TISSUE REGENERATIONDecember 2021May 2025Abandon4101NoNo
17622042ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXESDecember 2021December 2024Allow3600YesNo
17557567COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETYDecember 2021May 2025Allow4011NoNo
17617711ANTIBIOTIC POTENTIATION FOR NONTUBERCULOUS MYCOBACTERIAL DISEASEDecember 2021May 2025Abandon4101NoNo
17456033CANNABINOL-O-ACETATE SYNTHESIS, COMPOSITIONS, AND METHODS OF USENovember 2021February 2024Abandon2701NoNo
17609021PRODRUG COMPOUNDSNovember 2021May 2025Abandon4210NoNo
17499248RESIQUIMOD TOPICAL AND INJECTABLE COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN CONDITIONSOctober 2021April 2025Abandon4201NoNo
17492320ISOPROPYLCARBONATE BENZOYL PEROXIDE COMPOSITIONS AND METHODS OF USEOctober 2021March 2025Abandon4101NoNo
17442285SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORSSeptember 2021April 2025Abandon4310NoNo
17436885SMALL MOLECULE MODULATORS OF IL-17September 2021August 2024Allow3600YesNo
17436884COMPOSITIONS FOR PATHOGEN INACTIVATION OR PATHOGEN REDUCTION MANAGEMENTSeptember 2021March 2025Abandon4210NoNo
174331932-HETEROARYL AMINOQUINAZOLINONE DERIVATIVEAugust 2021May 2025Allow4521NoNo
17432485TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR V (RORV) -DEPENDENT CANCERSAugust 2021January 2025Abandon4101NoNo
17430219PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND RIBOCICLIBAugust 2021February 2025Allow4210YesNo
1731026815-PGDH INHIBITORSJuly 2021November 2024Allow4011YesNo
17423778HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTSJuly 2021December 2024Abandon4101NoNo
17374509NONIONIC POLYETHER SURFACTANTSJuly 2021October 2024Abandon3931NoNo
17422283NLRP3 MODULATORSJuly 2021August 2024Allow3711YesNo
17418323DIKETOPIPERAZINE DERIVATIVES AS CALCIUM ATPASE INHIBITOR FOR ENHANCING ANTICANCER ACTIVITYJune 2021August 2024Allow3810NoNo
17350581Compounds, Compositions and MethodsJune 2021August 2024Allow3801NoNo
17349862NOVEL IMIDAZOPYRAZINE DERIVATIVESJune 2021September 2024Abandon3901NoNo
17345688COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOFJune 2021December 2024Abandon4201NoNo
17413406PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENTJune 2021December 2024Allow4220NoNo
17312858COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCERJune 2021May 2024Allow3521NoNo
17312077Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine CompoundsJune 2021January 2025Allow4311YesNo
17312196SALIVARY GLAND REGENERATIONJune 2021January 2025Allow4411NoNo
17255707PHARMACEUTICAL COMPOSITION CONTAINING 9-ETHYL-6, 6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6, 11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILEJune 2021August 2024Allow4330YesNo
17311105TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OFJune 2021October 2024Abandon4001NoNo
17299741METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTORJune 2021June 2025Abandon4821NoNo
17299696(PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCERJune 2021June 2024Allow3611NoNo
17299634CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORSJune 2021November 2024Allow4220NoNo
17299733SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3June 2021February 2025Allow4521YesNo
17295327METHODS OF TREATING CANCERSMay 2021April 2025Abandon4721NoNo
17293157HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORSMay 2021September 2024Abandon4010NoNo
17306167PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVESMay 2021December 2024Allow4320NoNo
17288718DRUG FOR TREATING TINNITUSApril 2021November 2024Allow4311NoNo
17287137Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitorsApril 2021March 2024Allow3510NoNo
17286002DEUTERATED MELFLUFEN COMPOUNDSApril 2021July 2024Allow3911YesNo
17224902ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATIONApril 2021May 2025Abandon4921NoNo
17281525INDOLE MACROCYCLIC DERIVATIVE, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINEMarch 2021July 2024Abandon4010NoNo
17280245PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUGMarch 2021April 2024Allow3710YesNo
17279765METHODS OF TREATING MYELOPROLIFERATIVE DISORDERSMarch 2021June 2025Abandon5130NoNo
17278397NOVEL QUINAZOLINE EGFR INHIBITORSMarch 2021July 2024Abandon3901NoNo
17277759COMPOSITIONS AND METHODS FOR INHIBITING ACSS2March 2021November 2024Abandon4311NoNo
17277706COMPOSITION FOR INHIBITION OR TREATMENT OF BRAIN TUMORS OR SYMPTOMS ATTRIBUTABLE THERETOMarch 2021July 2024Abandon4010NoNo
17275918COMPOSITIONS AND METHODS FOR ENHANCING WOUND HEALINGMarch 2021June 2024Abandon3910NoNo
17195624COMPOUND, PREPARATION METHOD AND USE THEREOFMarch 2021December 2023Allow3310YesNo
171823756-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyTFebruary 2021May 2024Abandon3901NoNo
17267439SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCERFebruary 2021February 2025Allow4821NoNo
17164045ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITYFebruary 2021April 2024Allow3810NoNo
17264684BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORSJanuary 2021April 2024Allow3921NoNo
17263164MEDICINAL PRODUCT, ANTICANCER AGENT, MEDICINAL INTERMEDIATE PRODUCT, AND METHOD FOR PRODUCING CYCLIC CARBOXYLIC ACID COMPOUND OR DERIVATIVE THEREOFJanuary 2021March 2024Abandon3801NoNo
17262452TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOFJanuary 2021April 2024Allow3920NoNo
17104770METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOFNovember 2020April 2024Abandon4101NoNo
17081291STABLE PHARMACEUTICAL COMPOSITIONSOctober 2020July 2024Abandon4511NoNo
17046663CONVERSION OF 1,2,5,6-HEXANETETROL (HTO) TO TETRAHYDROFURAN dicarboxylic acid (THFDCA)October 2020January 2024Allow4010NoNo
17043017PROCESS FOR MAKING SARECYCLINE HYDROCHLORIDESeptember 2020August 2024Allow4720NoNo
16904358COMPOSITIONS AND METHODS FOR DIAGNOSING URINARY TRACT INFECTIONSJune 2020July 2024Abandon4920NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner NOTTINGHAM, KYLE GREGORY - Prosecution Strategy Guide

Executive Summary

Examiner NOTTINGHAM, KYLE GREGORY works in Art Unit 1621 and has examined 76 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.

Allowance Patterns

Examiner NOTTINGHAM, KYLE GREGORY's allowance rate of 52.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by NOTTINGHAM, KYLE GREGORY receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by NOTTINGHAM, KYLE GREGORY is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +47.5% benefit to allowance rate for applications examined by NOTTINGHAM, KYLE GREGORY. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 72.7% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.0% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.